Onglyza Lawsuit Evaluations Offered by Bernstein Liebhard LLP In Response to FDA Warning on Saxagliptin and Heart Failure

NEW YORK, July 13, 2017 /PRNewswire/ -- The nationwide law firm of Bernstein Liebhard LLP is offering Onglyza lawsuit evaluations to individuals who were diagnosed with heart failure or other cardiac problems following treatment with Onglyza or Kombiglyze XR. In April 2016, the drugs' labels were updated to note this possible risk after a clinical trial suggested that saxagliptin was associated with a 27% increase in hospitalizations for heart failure.

"Our Firm has heard from a number of individuals who allegedly developed heart failure following treatment with Onglyza or Kombiglyze XR. At the same time, a growing number of Onglyza lawsuits have been filed in U.S. courts," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. 

Onglyza and Heart Failure

Onglyza (saxagliptin) was approved by the U.S. Food & Drug Administration (FDA) in 2009, and is used in conjunction with diet and exercise to lower blood glucose in people with Type 2 diabetes. The agency approved Kombiglyze XR (saxagliptin and metformin)  in November 2010.

The FDA launched a safety review of all saxagliptin-containing medications in 2014, after the SAVOR-TMI clinical trial suggested that Onglyza and Kombiglyze XR were associated with a 27% increase in hospitalizations for heart failure, as well as a higher risk of all-cause mortality.

On April 14, 2015, a panel of FDA advisors voted 14-to-1 to recommend the prescribing information for Onglyza and Kombiglyze XR be modified with information regarding the potential link to heart failure. The labels' "Warning and Precautions" sections were updated the following year.

In May, the National Law Journal reported that product liability lawsuits involving Onglyza and Kombiglyze XR were mounting in courts through the U.S. Plaintiffs claim that treatment with saxagliptin raises the risk of heart failure and accuse AstraZeneca and Bristol-Myers Squibb of failing to warn of its alleged potential to cause cardiac arrest, congestive heart failure and death.

Type 2 diabetes patients who were diagnosed with heart failure while using Onglyza or Kombiglyze XR could be entitled to compensation for medical bills, lost wages, pain and suffering and more. To obtain a free case evaluation, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP  
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 
800-511-5092

ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information: 
Sandy A. Liebhard, Esq. 
Bernstein Liebhard LLP 
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/  
https://plus.google.com/115936073311125306742?rel=author

SOURCE Bernstein Liebhard LLP

Related Links

http://www.bernlieb.com